STOCKHOLM, May 14, 2019 /PRNewswire/ — The Annual General Meeting (the “AGM”) on May 14, 2019 decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2018. Furthermore, it was decided that no dividend will be distributed and disposable profits as of 2018-12-31 are carried forward to future periods.
The AGM also decided to discharge the board members and the CEO from liability for 2018.
The AGM approved the nominating committee’s proposal that the board shall consist of six board members.
The AGM decided that the total board renumeration shall amount to SEK 1,946,000 whereof the remuneration to the chairman of the board shall amount to SEK 540,000 and that the remuneration to the other board members not employed by the company shall be SEK 240,000 each. For the elected not employed board member living in the US an additional remuneration of SEK 96,000 is paid. The renumeration to the chairmen in the audit and remuneration committee is SEK 100,000 each and SEK 50,000 each to the other members in the committees. The AGM also decided that the remuneration to the auditor, as previous, will be on specified current account.
The AGM decided that the board until the end of the next AGM meeting will consist of the members Anders P. Wiklund, Kleanthis G. Xanthopoulos, Marios Fotiadis, Anita Tollstadius, Eva Nilsagård and Catherine Gilmore-Lawless. Anders P. Wiklund was re-elected chairman of the board. KPMG AB was re-elected as the company’s auditor, with Duane Swanson as auditor in charge, until the end of the AGM of 2019.
The AGM approved the board’s proposed remuneration guidelines for senior management.
The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares and/or convertibles.
Complete proposals regarding the AGM’s decisions are available on IRRAS AB:s website www.irras.com.
For more information, please contact:
CFO and Deputy CEO
+46 706 67 31 06
IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery.
The company’s initial product, IRRAflow®, is the world’s first “irrigating ventricular drain.” Its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Additionally, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels. IRRAflow received FDA-clearance in July 2018.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco is certified adviser of the company. Wildeco is reached at + 46 8 545 271 00 or at email@example.com.
The information was released for public disclosure, through the agency of the contact person above, on May 14, 2019 at 07.30 p.m. (CET).
This information was brought to you by Cision http://news.cision.com
The following files are available for download: